Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Current clinical tools rely on known cardiovascular risk elements, but they often do not account for complex interactions ...

Noncardiac conditions, such as a blood clot in the lung or hyperthyroidism, may also cause atrial fibrillation. What is the drug of choice for atrial fibrillation? There is no single drug of choice ...

Do scary movies make your heart skip a beat? Or maybe you notice a flutter in your chest just as you’re settling down for the ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Bimagrumab, a drug originally developed for muscle loss, may help reduce the risk of osteoporosis in weight loss medication ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.